CDKN2A and meningioma: The median PFS time in the patients with WHO grade 1 or 2 meningiomas combined with a heterozygous CDKN2A/B deletion was 32.1 months (95% CI 22.7–41.5 months), and in those with a WHO 1, 2 or 3 meningioma combined with a CDKN2A/B wild-type was 180.0 months (95% CI 141.4–218.6 months), respectively (log-rank test: p < 0.0001).